Scenarios that move AMGN
Amgen Inc. - Common Stock
Scenarios that move AMGN: 24 analyses, 5 positive, 19 negative.
- · RARE's Fayuvi approval triggers second $203 million PRV sale — ▼ · impact -52 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -37 · confidence medium · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▼ · impact -22 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +32 · confidence medium · horizon weeks
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +14 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▲ · impact +32 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▼ · impact -25 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -20 · confidence medium · horizon quarters
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▲ · impact +30 · confidence low · horizon weeks
- · Liquidia stock plunges 57% after UTHR patent setback — ▼ · impact -25 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -36 · confidence medium · horizon weeks
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▼ · impact -25 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▼ · impact -50 · confidence medium · horizon weeks
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▼ · impact -10 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -30 · confidence medium · horizon weeks
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▲ · impact +35 · confidence low · horizon weeks
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -30 · confidence medium · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -25 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▼ · impact -47 · confidence medium · horizon weeks
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▼ · impact -57 · confidence medium · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -15 · confidence medium · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▼ · impact -37 · confidence medium · horizon weeks
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▼ · impact -72 · confidence high · horizon immediate
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▼ · confidence low